Samplesidentify PIs NRTIs NNRTIs 1st generation NNRTIs 2nd generation Drugs still efficient for a third line regimen with INI ATV/r DRV/r FPV/r IDV/r LPV/r NFV SQV/r TPV/r 3TC ABC AZT D4T DDI FTC TDF NVP EFV ETV RPV 101_FL LLR S LLR IR LLR HLR IR S HLR IR IR IR LLR HLR S HLR HLR IR HLR DRV/r, TPV/r, TDF 101_SL LLR S LLR IR LLR HLR IR S HLR IR IR IR LLR HLR S HLR HLR IR HLR 1523_FL S S S S S PLLR S S HLR IR IR IR IR HLR PPLR HLR HLR IR HLR ATV/r, DRV/r, FPV/r, LPV/r, NFV 1523_SL S S S S S PLLR S S HLR LLR S S PLLR HLR S HLR HLR IR HLR 1837_FL S S S S S S S S HLR HLR HLR HLR HLR HLR HLR HLR HLR IR IR None efficient drugs 1837_SL IR HLR HLR HLR HLR HLR HLR HLR HLR HLR HLR HLR HLR HLR HLR S S S S 2107_FL NG NG NG NG NG NG NG NG NG NG NG NG NG NG NG NG NA NG NG ATV/r, DRV/r, FPV/r, IDV/r, LPV/r, NFV, SQV/r, TPV/r 2107_SL S S S S S PLLR S S HLR IR HLR HLR IR HLR LLR HLR HLR LLR LLR 2401_FL S S S S S S S S HLR HLR HLR HLR HLR HLR HLR HLR HLR PLLR LLR ATV/r, DRV/r, FPV/r, IDV/r, LPV/r, NFV, SQV/r, TPV/r 2401_SL S S S S S PLLR S S HLR HLR HLR HLR HLR HLR HLR HLR HLR PLLR LLR 478_FL S S S S S PLLR S S HLR LLR S S PLLR R S HLR HLR LLR IR DRV/r, AZT, D4T, TDF 478_SL LLR S LLR LLR LLR IR LLR IR S S   S S S S S S S S 2931_FL S S S S S S S S HLR LLR S S PLLR HLR S HLR HLR S S ATV/r, DRV/r, FPV/r, IDV/r, LPV/r, NFV, SQV/r, TPV/r, AZT, D4T, ETV, RPV 2931_SL S S S S S S S S S S S S S S S S S S S 3259_FL IR LLR IR IR IR HLLR IR LLR HLR IR IR IR IR HLR LLR S S S S NVP, EFV, ETV, RPV 3259_SL HLR IR HLR HLR HLR HLR IR LLR HLR HLR HLR IR HLR HLR IR S S S S 4039_FL S S S S S S S S S S S S S S S HLR HLR IR IR ATV/r, DRV/r, FPV/r, IDV/r, LPV/r, NFV, SQV/r, TPV/r, 3TC, ABC, AZT, D4T, FTC, TDF 4039_SL S S S S S S S S S S S S PLLR S S S S S S 8253_FL S S S S S PLLR S S HLR IR IR LLR LLR HLR S HLR HLR S S ATV/r, DRV/r, FPV/r, IDV/r, LPV/r, NFV, SQV/r, TPV/r, ETV, RPV 8253_SL S S S S S PLLR S S HLR IR IR LLR LLR HLR S HLR HLR S S 929_FL LLR S LLR IR LLR HLR IR S HLR HLR HLR HLR HLR HLR HLR HLR HLR HLR HLR None efficient drugs 929_SL HLR LLR HLR HLR IR HLR HLR IR HLR HLR HLR HLR HLR HLR HLR HLR HLR IR HLR 2698_FL S S S S S S S S HLR LLR S S PLLR HLR S HLR HLR LLR HLR ATV/r, DRV/r, FPV/r, IDV/r, LPV/r, NFV, SQV/r, TPV/r, AZT, D4T, TDF 2698_SL S S S S S PLLR S S HLR LLR S S PLLR HLR S HLR HLR LLR HLR

Table 1: Drugs still efficient that could be associated with Integrase Inhibitors (INI) for third line regimen. S: Sensible, LLR: Low level resistance, IR: Intermediate resistance, PLLR: Potential low level resistance, HLR: High level resistance, R: resistance, FS: first line, SL: second line, NG: Not genotyped, PIs: Protease inhibitors, NRTIs: Nucleoside reverse transcriptase inhibitors, NNRTIs: Non-nucleoside reverse transcriptase inhibitors, INI: Integrase inhibitor, 1st: First, 2nd: Second. AZT: Zidovudine, 3TC: Lamivudine, FTC: Emtricitabine, D4T: Stavudine, NVP: Névirapine, EFV: Efavirenz, ETV: Etravirine, RPV: Rilpivirine, DDI: Didanosine, TDF: Tenofovir, ABC: Abacavir, LPV: Lopinavir, ATV: Atazanavir, IDV: Indinavir, r: Ritonavir, TPV: Tripanavir, DRV: Darunavir, FPV: Fosamprenavir, NFV: Nelfinavir, SQV: Saquinavir.

Goto home»